Establishment Labs Holdings Inc.
ESTA Nasdaq Orthopedic, Prosthetic & Surgical Appliances & Supplies Financials FY2017βFY2025
What Establishment Labs Holdings Inc. does
No business description yet.
- Legal name
- ESTABLISHMENT LABS HOLDINGS INC.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Feb 27, 2026
- Accession Β· CIK
- 0001688757-26-000022
0001688757
Revenue and margins
Establishment Labs Holdings Inc. had $211M of revenue in fiscal 2025, up 27.1% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$56.9M in fiscal 2025, β27.0% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Establishment Labs Holdings Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 5.2%.
Balance sheet
Cash, debt and the ratios that show how comfortably Establishment Labs Holdings Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $53.4M | $66.4M | $40.0M | $90.3M | $75.6M |
| Debt incl. finance leases | $51.9M | $175M | $189M | $0.0M | $248M |
| Debt / equity | 1.0x | β | 10.3x | 0.0x | 10.5x |
| Interest coverage | β2.8x | β3.4x | β4.2x | β2.4x | β1.5x |
| Current ratio | 3.6x | 3.8x | 3.1x | 3.6x | 3.0x |
| Quick ratio | 2.7x | 2.9x | 1.7x | 2.4x | 2.0x |
| Total assets | $140M | $211M | $269M | $347M | $357M |
| Total liabilities | $88.8M | $219M | $250M | $294M | $334M |
| Shareholders' equity | $50.7M | β$8.2M | $18.4M | $53.1M | $23.5M |
| Net debt (β = net cash) | β$1.5M | $109M | $149M | β$90.3M | $172M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 8 | 3 / 8 | 5 / 9 | 3 / 9 | 2 / 9 | 2 / 9 | 5 / 9 | 4 / 9 |
| Accruals ratio | β5.1% | 14.7% | β7.0% | β18.8% | β9.2% | β13.1% | 4.2% | β8.5% | β0.0% |
| Altman Z'' | β8.39 | 2.36 | β0.71 | 0.79 | β1.61 | β2.20 | β3.04 | β1.65 | β2.10 |
9 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | $34.7M | $61.2M | $89.6M | $84.7M | $127M | $162M | $165M | $166M | $211M |
| Gross profit | $17.7M | $36.1M | $54.9M | $52.5M | $85.4M | $107M | $107M | $110M | $146M |
| Research and development | $6.9M | $12.7M | $15.0M | $13.8M | $18.3M | $20.3M | $26.4M | $19.7M | $20.2M |
| Operating income | β$20.0M | β$23.9M | β$30.9M | β$27.9M | β$25.1M | β$39.7M | β$65.0M | β$50.0M | β$39.0M |
| Interest expense | $10.4M | $8.8M | $8.7M | $9.4M | $9.1M | $11.8M | $15.4M | $20.8M | $25.3M |
| Pretax income | β$34.8M | β$20.9M | β$37.5M | β$38.0M | β$39.7M | β$72.8M | β$78.6M | β$84.6M | β$58.0M |
| Income tax | $0.1M | $0.2M | $0.6M | $0.1M | $1.4M | $2.4M | β$0.1M | β$0.0M | β$7.0M |
| Net income | β$34.9M | β$21.1M | β$38.2M | β$38.1M | β$41.1M | β$75.2M | β$78.5M | β$84.6M | β$51.1M |
| Diluted EPS | β$3.41 | β$1.22 | β$1.86 | β$1.63 | β$1.72 | β$3.08 | β$3.07 | β$3.00 | β$1.72 |
| Diluted shares | 0.01B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.03B | 0.03B | 0.03B |
| Cash flow | |||||||||
| Cash from operations | β$32.0M | β$33.9M | β$30.0M | β$12.5M | β$27.5M | β$52.2M | β$88.5M | β$58.5M | β$50.9M |
| Capital expenditure | $0.9M | $1.7M | $6.3M | $2.1M | $2.4M | $2.9M | $7.9M | $6.1M | $6.0M |
| Free cash flow | β$32.9M | β$35.6M | β$36.3M | β$14.6M | β$30.0M | β$55.0M | β$96.4M | β$64.6M | β$56.9M |
| Depreciation and amortization | β | β | β | β | $2.5M | $2.5M | $2.8M | $4.7M | $6.2M |
| Stock-based compensation | β | $7.3M | $6.5M | $5.7M | $10.4M | $13.4M | $14.4M | $14.4M | $11.4M |
| Acquisitions | β | β | β | β | β | $0.0M | $0.0M | $0.1M | $0.3M |
| Share buybacks | $4.5M | $0.0M | β | β | β | β | β | β | β |
| Dividends and buybacks | $4.5M | $0.0M | β | β | β | β | β | β | β |
| Balance sheet | |||||||||
| Cash and short-term investments | $10.9M | $52.6M | $37.7M | $84.5M | $53.4M | $66.4M | $40.0M | $90.3M | $75.6M |
| Total debt | β | β | $48.1M | $49.8M | $51.9M | $175M | $189M | $0.0M | $248M |
| Finance lease liabilities | β | β | β | $0.2M | $0.0M | β | β | β | β |
| Current assets | $39.4M | $99.4M | $95.8M | $132M | $113M | $150M | $175M | $243M | $250M |
| Current liabilities | $57.4M | $16.4M | $23.2M | $25.9M | $31.9M | $39.0M | $57.2M | $68.3M | $82.1M |
| Inventory | $13.2M | $24.8M | $28.7M | $23.2M | $28.4M | $36.6M | $79.5M | $78.8M | $85.6M |
| Property and equipment, net | $13.5M | $12.9M | $16.4M | $16.2M | $18.7M | $51.1M | $77.2M | $78.0M | $75.6M |
| Goodwill | $0.5M | $0.5M | $0.5M | $0.5M | $0.5M | $0.5M | $0.5M | $1.2M | $1.2M |
| Intangible assets | $3.4M | $3.4M | $3.4M | $4.1M | $4.4M | $4.6M | $8.0M | $11.7M | $9.9M |
| Total assets | $57.1M | $117M | $117M | $156M | $140M | $211M | $269M | $347M | $357M |
| Total liabilities | $62.1M | $47.1M | $76.9M | $81.4M | $88.8M | $219M | $250M | $294M | $334M |
| Shareholders' equity | β$5.0M | $69.5M | $39.6M | $75.0M | $50.7M | β$8.2M | $18.4M | $53.1M | $23.5M |
| Margins | |||||||||
| Gross margin | 51.0% | 59.0% | 61.3% | 62.0% | 67.4% | 65.9% | 64.8% | 66.0% | 69.3% |
| Operating margin | β57.6% | β39.0% | β34.5% | β33.0% | β19.8% | β24.5% | β39.4% | β30.1% | β18.5% |
| EBITDA margin | β | β | β | β | β17.9% | β23.0% | β37.7% | β27.3% | β15.5% |
| Net margin | β100.6% | β34.5% | β42.6% | β45.0% | β32.5% | β46.5% | β47.5% | β51.0% | β24.2% |
| FCF margin | β94.8% | β58.2% | β40.5% | β17.3% | β23.6% | β34.0% | β58.4% | β38.9% | β27.0% |
| Returns | |||||||||
| Return on capital | β | β | β48.8% | β54.8% | β40.3% | β31.0% | β30.7% | β | β15.8% |
| Return on capital employed | 5,877.4% | β23.8% | β33.2% | β21.4% | β23.4% | β23.0% | β30.7% | β17.9% | β14.2% |
| Return on equity | β | β65.4% | β69.9% | β66.5% | β65.5% | β353.5% | β1,537.7% | β236.7% | β133.3% |
| Return on assets | β61.1% | β24.3% | β32.7% | β27.9% | β27.8% | β42.9% | β32.7% | β27.5% | β14.5% |
| Return on tangible equity | β | β32.2% | β106.8% | β54.2% | β89.6% | β | β789.5% | β210.4% | β411.9% |
| Growth | |||||||||
| Revenue growth | β | 76.5% | 46.3% | β5.5% | 49.6% | 27.6% | 2.1% | 0.5% | 27.1% |
| Share count change | β | 69.6% | 18.4% | 13.5% | 2.8% | 2.0% | 4.7% | 10.0% | 5.2% |
| Financial health | |||||||||
| Debt / equity | β | β | 1.2x | 0.7x | 1.0x | β | 10.3x | 0.0x | 10.5x |
| Interest coverage | β1.9x | β2.7x | β3.6x | β3.0x | β2.8x | β3.4x | β4.2x | β2.4x | β1.5x |
| Current ratio | 0.7x | 6.0x | 4.1x | 5.1x | 3.6x | 3.8x | 3.1x | 3.6x | 3.0x |
| Quick ratio | 0.5x | 4.5x | 2.9x | 4.2x | 2.7x | 2.9x | 1.7x | 2.4x | 2.0x |
| Capital allocation | |||||||||
| Capex / revenue | 2.6% | 2.8% | 7.0% | 2.5% | 1.9% | 1.8% | 4.8% | 3.7% | 2.9% |
| Stock comp / revenue | β | 12.0% | 7.3% | 6.8% | 8.2% | 8.3% | 8.7% | 8.7% | 5.4% |
| Quality scores | |||||||||
| Piotroski F-score | β | 3.0 | 3.0 | 5.0 | 3.0 | 2.0 | 2.0 | 5.0 | 4.0 |
| Altman Z'' | β8.4 | 2.4 | β0.7 | 0.8 | β1.6 | β2.2 | β3.0 | β1.7 | β2.1 |
| Accruals ratio | β5.1% | 14.7% | β7.0% | β18.8% | β9.2% | β13.1% | 4.2% | β8.5% | β0.0% |
Source: SEC EDGAR XBRL filings (CIK 0001688757). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.